Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Efficacy of Human Exposures of Gepotidacin (GSK2140944) against Escherichia coli in a Rat Pyelonephritis Model.

Hoover JL, Singley CM, Elefante P, Rittenhouse S.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00086-19. doi: 10.1128/AAC.00086-19. Print 2019 Jul.

2.

Effective Three-Body Interactions in Cs(6s)-Cs(nd) Rydberg Trimers.

Fey C, Yang J, Rittenhouse ST, Munkes F, Baluktsian M, Schmelcher P, Sadeghpour HR, Shaffer JP.

Phys Rev Lett. 2019 Mar 15;122(10):103001. doi: 10.1103/PhysRevLett.122.103001.

PMID:
30932632
3.

Ultracold Rydberg molecules.

Shaffer JP, Rittenhouse ST, Sadeghpour HR.

Nat Commun. 2018 May 17;9(1):1965. doi: 10.1038/s41467-018-04135-6. Review.

4.

Efimov States of Strongly Interacting Photons.

Gullans MJ, Diehl S, Rittenhouse ST, Ruzic BP, D'Incao JP, Julienne P, Gorshkov AV, Taylor JM.

Phys Rev Lett. 2017 Dec 8;119(23):233601. doi: 10.1103/PhysRevLett.119.233601. Epub 2017 Dec 4.

PMID:
29286689
5.

Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats.

Hoover JL, Singley CM, Elefante P, DeMarsh P, Zalacain M, Rittenhouse S.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00959-17. doi: 10.1128/AAC.00959-17. Print 2017 Nov.

6.

Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics.

Matsumoto S, Singley CM, Hoover J, Nakamura R, Echols R, Rittenhouse S, Tsuji M, Yamano Y.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00700-17. doi: 10.1128/AAC.00700-17. Print 2017 Sep.

7.

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii.

Hoover JL, Lewandowski TF, Mininger CL, Singley CM, Sucoloski S, Rittenhouse S.

J Vis Exp. 2017 Jan 2;(119). doi: 10.3791/55068.

8.

Theory of Ultralong-Range Rydberg Molecule Formation Incorporating Spin-Dependent Relativistic Effects: Cs(6s)-Cs(np) as Case Study.

Markson S, Rittenhouse ST, Schmidt R, Shaffer JP, Sadeghpour HR.

Chemphyschem. 2016 Nov 18;17(22):3683-3691. doi: 10.1002/cphc.201600932. Epub 2016 Oct 31.

PMID:
27712011
9.

Electric Field Cancellation on Quartz by Rb Adsorbate-Induced Negative Electron Affinity.

Sedlacek JA, Kim E, Rittenhouse ST, Weck PF, Sadeghpour HR, Shaffer JP.

Phys Rev Lett. 2016 Apr 1;116(13):133201. doi: 10.1103/PhysRevLett.116.133201. Epub 2016 Mar 30.

PMID:
27081976
10.

Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases.

Miles TJ, Hennessy AJ, Bax B, Brooks G, Brown BS, Brown P, Cailleau N, Chen D, Dabbs S, Davies DT, Esken JM, Giordano I, Hoover JL, Jones GE, Kusalakumari Sukmar SK, Markwell RE, Minthorn EA, Rittenhouse S, Gwynn MN, Pearson ND.

Bioorg Med Chem Lett. 2016 May 15;26(10):2464-2469. doi: 10.1016/j.bmcl.2016.03.106. Epub 2016 Mar 31.

PMID:
27055939
11.

In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria.

Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R, Tsuji M, Yamano Y.

J Antimicrob Chemother. 2016 Mar;71(3):670-7. doi: 10.1093/jac/dkv402. Epub 2015 Dec 7.

PMID:
26645269
12.

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.

Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y.

Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34. doi: 10.1128/AAC.01695-15. Print 2016 Feb.

13.

Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.

Hoover J, Lewandowski T, Straub RJ, Novick SJ, DeMarsh P, Aubart K, Rittenhouse S, Zalacain M.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):180-9. doi: 10.1128/AAC.01842-15. Print 2016 Jan.

14.

Molecular physics. Production of trilobite Rydberg molecule dimers with kilo-Debye permanent electric dipole moments.

Booth D, Rittenhouse ST, Yang J, Sadeghpour HR, Shaffer JP.

Science. 2015 Apr 3;348(6230):99-102. doi: 10.1126/science.1260722.

15.

Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections.

O'Dwyer K, Spivak AT, Ingraham K, Min S, Holmes DJ, Jakielaszek C, Rittenhouse S, Kwan AL, Livi GP, Sathe G, Thomas E, Van Horn S, Miller LA, Twynholm M, Tomayko J, Dalessandro M, Caltabiano M, Scangarella-Oman NE, Brown JR.

Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. doi: 10.1128/AAC.03774-14. Epub 2014 Oct 27.

16.

Spin waves and dielectric softening of polar molecule condensates.

Wilson RM, Peden BM, Clark CW, Rittenhouse ST.

Phys Rev Lett. 2014 Apr 4;112(13):135301. Epub 2014 Apr 1.

PMID:
24745433
17.

Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases.

Miles TJ, Hennessy AJ, Bax B, Brooks G, Brown BS, Brown P, Cailleau N, Chen D, Dabbs S, Davies DT, Esken JM, Giordano I, Hoover JL, Huang J, Jones GE, Sukmar SK, Spitzfaden C, Markwell RE, Minthorn EA, Rittenhouse S, Gwynn MN, Pearson ND.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5437-41. doi: 10.1016/j.bmcl.2013.07.013. Epub 2013 Jul 17.

PMID:
23968823
18.

Observation of blueshifted ultralong-range Cs2 Rydberg molecules.

Tallant J, Rittenhouse ST, Booth D, Sadeghpour HR, Shaffer JP.

Phys Rev Lett. 2012 Oct 26;109(17):173202. Epub 2012 Oct 23.

PMID:
23215184
19.

First-order phase transitions in optical lattices with tunable three-body onsite interaction.

Safavi-Naini A, von Stecher J, Capogrosso-Sansone B, Rittenhouse ST.

Phys Rev Lett. 2012 Sep 28;109(13):135302. Epub 2012 Sep 28.

PMID:
23030100
20.

A homonuclear molecule with a permanent electric dipole moment.

Li W, Pohl T, Rost JM, Rittenhouse ST, Sadeghpour HR, Nipper J, Butscher B, Balewski JB, Bendkowsky V, Löw R, Pfau T.

Science. 2011 Nov 25;334(6059):1110-4. doi: 10.1126/science.1211255.

21.

Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases.

Miles TJ, Axten JM, Barfoot C, Brooks G, Brown P, Chen D, Dabbs S, Davies DT, Downie DL, Eyrisch S, Gallagher T, Giordano I, Gwynn MN, Hennessy A, Hoover J, Huang J, Jones G, Markwell R, Miller WH, Minthorn EA, Rittenhouse S, Seefeld M, Pearson N.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7489-95. doi: 10.1016/j.bmcl.2011.09.117. Epub 2011 Oct 10.

PMID:
22047689
22.

Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases.

Miles TJ, Barfoot C, Brooks G, Brown P, Chen D, Dabbs S, Davies DT, Downie DL, Eyrisch S, Giordano I, Gwynn MN, Hennessy A, Hoover J, Huang J, Jones G, Markwell R, Rittenhouse S, Xiang H, Pearson N.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7483-8. doi: 10.1016/j.bmcl.2011.09.114. Epub 2011 Oct 10.

PMID:
22030032
23.

Rydberg atom mediated polar molecule interactions: a tool for molecular-state conditional quantum gates and individual addressability.

Kuznetsova E, Rittenhouse ST, Sadeghpour HR, Yelin SF.

Phys Chem Chem Phys. 2011 Oct 14;13(38):17115-21. doi: 10.1039/c1cp21476d. Epub 2011 Aug 24.

PMID:
21869969
24.

Challenges of antibacterial discovery revisited.

Gwynn MN, Portnoy A, Rittenhouse SF, Payne DJ.

Ann N Y Acad Sci. 2010 Dec;1213:5-19. doi: 10.1111/j.1749-6632.2010.05828.x. Epub 2010 Nov 8. Review.

PMID:
21058956
25.

Three body recombination of ultracold dipoles to weakly bound dimers.

Ticknor C, Rittenhouse ST.

Phys Rev Lett. 2010 Jul 2;105(1):013201. Epub 2010 Jul 2.

PMID:
20867441
26.

Ultracold giant polyatomic Rydberg molecules: coherent control of molecular orientation.

Rittenhouse ST, Sadeghpour HR.

Phys Rev Lett. 2010 Jun 18;104(24):243002. Epub 2010 Jun 15.

PMID:
20867298
27.

A rapid microtiter plate assay for measuring the effect of compounds on Staphylococcus aureus membrane potential.

Gentry DR, Wilding I, Johnson JM, Chen D, Remlinger K, Richards C, Neill S, Zalacain M, Rittenhouse SF, Gwynn MN.

J Microbiol Methods. 2010 Nov;83(2):254-6. doi: 10.1016/j.mimet.2010.08.012. Epub 2010 Aug 27.

PMID:
20801170
28.

General theoretical description of N-body recombination.

Mehta NP, Rittenhouse ST, D'Incao JP, von Stecher J, Greene CH.

Phys Rev Lett. 2009 Oct 9;103(15):153201. Epub 2009 Oct 9.

PMID:
19905635
29.

Collective coordinate description of anisotropically trapped degenerate Fermi gases.

Rittenhouse ST, Cavagnero MJ, Greene CH.

J Phys Chem A. 2009 Dec 31;113(52):15016-23. doi: 10.1021/jp9051006.

PMID:
19899802
30.

Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus.

Gentry DR, McCloskey L, Gwynn MN, Rittenhouse SF, Scangarella N, Shawar R, Holmes DJ.

Antimicrob Agents Chemother. 2008 Dec;52(12):4507-9. doi: 10.1128/AAC.00915-08. Epub 2008 Oct 6.

31.
32.

Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic.

Rittenhouse S, Singley C, Hoover J, Page R, Payne D.

Antimicrob Agents Chemother. 2006 Nov;50(11):3886-8.

33.

Selection of retapamulin, a novel pleuromutilin for topical use.

Rittenhouse S, Biswas S, Broskey J, McCloskey L, Moore T, Vasey S, West J, Zalacain M, Zonis R, Payne D.

Antimicrob Agents Chemother. 2006 Nov;50(11):3882-5.

34.

Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues.

Jarvest RL, Armstrong SA, Berge JM, Brown P, Elder JS, Brown MJ, Copley RC, Forrest AK, Hamprecht DW, O'Hanlon PJ, Mitchell DJ, Rittenhouse S, Witty DR.

Bioorg Med Chem Lett. 2004 Aug 2;14(15):3937-41.

PMID:
15225702
35.

New benzylidenethiazolidinediones as antibacterial agents.

Heerding DA, Christmann LT, Clark TJ, Holmes DJ, Rittenhouse SF, Takata DT, Venslavsky JW.

Bioorg Med Chem Lett. 2003 Nov 3;13(21):3771-3.

PMID:
14552776
36.

Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes.

Gentry DR, Ingraham KA, Stanhope MJ, Rittenhouse S, Jarvest RL, O'Hanlon PJ, Brown JR, Holmes DJ.

Antimicrob Agents Chemother. 2003 Jun;47(6):1784-9.

37.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF.

J Med Chem. 2003 Apr 24;46(9):1627-35.

PMID:
12699381
38.

Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-positive antibacterial activity.

Jarvest RL, Berge JM, Brown P, Houge-Frydrych CS, O'Hanlon PJ, McNair DJ, Pope AJ, Rittenhouse S.

Bioorg Med Chem Lett. 2003 Apr 7;13(7):1265-8.

PMID:
12657260
39.

Optimisation of aryl substitution leading to potent methionyl tRNA synthetase inhibitors with excellent gram-positive antibacterial activity.

Jarvest RL, Berge JM, Brown MJ, Brown P, Elder JS, Forrest AK, Houge-Frydrych CS, O'Hanlon PJ, McNair DJ, Rittenhouse S, Sheppard RJ.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):665-8.

PMID:
12639554
40.

Spironolactone for heart failure: a worthy addition to therapy.

Rittenhouse SK.

Adv Nurse Pract. 2001 Jan;9(1):34-6, 39. Review. No abstract available.

PMID:
12416036
41.

Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus.

Fan F, Yan K, Wallis NG, Reed S, Moore TD, Rittenhouse SF, DeWolf WE Jr, Huang J, McDevitt D, Miller WH, Seefeld MA, Newlander KA, Jakas DR, Head MS, Payne DJ.

Antimicrob Agents Chemother. 2002 Nov;46(11):3343-7.

42.

Discovery of a novel and potent class of FabI-directed antibacterial agents.

Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf WE Jr, Fosberry AP, Greenwood R, Head MS, Heerding DA, Janson CA, Jaworski DD, Keller PM, Manley PJ, Moore TD, Newlander KA, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Salyers KL, Seefeld MA, Smyth MG, Takata DT, Uzinskas IN, Vaidya K, Wallis NG, Winram SB, Yuan CC, Huffman WF.

Antimicrob Agents Chemother. 2002 Oct;46(10):3118-24.

43.

Human platelets contain p110delta phosphoinositide 3-kinase.

Zhang J, Vanhaesebroeck B, Rittenhouse SE.

Biochem Biophys Res Commun. 2002 Aug 9;296(1):178-81.

PMID:
12147247
44.

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).

Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CC, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE Jr, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF.

J Med Chem. 2002 Jul 18;45(15):3246-56.

PMID:
12109908
45.

Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit.

Chan TO, Rodeck U, Chan AM, Kimmelman AC, Rittenhouse SE, Panayotou G, Tsichlis PN.

Cancer Cell. 2002 Mar;1(2):181-91.

46.

Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases.

Payne DJ, Hueso-Rodríguez JA, Boyd H, Concha NO, Janson CA, Gilpin M, Bateson JH, Cheever C, Niconovich NL, Pearson S, Rittenhouse S, Tew D, Díez E, Pérez P, De La Fuente J, Rees M, Rivera-Sagredo A.

Antimicrob Agents Chemother. 2002 Jun;46(6):1880-6.

47.

Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens.

Jarvest RL, Berge JM, Berry V, Boyd HF, Brown MJ, Elder JS, Forrest AK, Fosberry AP, Gentry DR, Hibbs MJ, Jaworski DD, O'Hanlon PJ, Pope AJ, Rittenhouse S, Sheppard RJ, Slater-Radosti C, Worby A.

J Med Chem. 2002 May 9;45(10):1959-62.

PMID:
11985462
49.

Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.

Seefeld MA, Miller WH, Newlander KA, Burgess WJ, Payne DJ, Rittenhouse SF, Moore TD, DeWolf WE Jr, Keller PM, Qiu X, Janson CA, Vaidya K, Fosberry AP, Smyth MG, Jaworski DD, Slater-Radosti C, Huffman WF.

Bioorg Med Chem Lett. 2001 Sep 3;11(17):2241-4.

PMID:
11527706
50.

1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).

Heerding DA, Chan G, DeWolf WE, Fosberry AP, Janson CA, Jaworski DD, McManus E, Miller WH, Moore TD, Payne DJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Smith W, Takata DT, Vaidya KS, Yuan CC, Huffman WF.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2061-5.

PMID:
11514139

Supplemental Content

Loading ...
Support Center